• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Inc (NQ: PRLD )

1.240 +0.040 (+3.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 377,281
Open 1.250
Bid (Size) 1.250 (5)
Ask (Size) 1.330 (1)
Prev. Close 1.200
Today's Range 1.240 - 1.338
52wk Range 1.100 - 6.800
Shares Outstanding 54,808,715
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
October 24, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
October 09, 2024
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) 
From Prelude Therapeutics, Incorporated
Via GlobeNewswire

Performance

YTD
-69.53%
-69.53%
1 Month
-34.39%
-34.39%
3 Month
-75.78%
-75.78%
6 Month
-67.62%
-67.62%
1 Year
-45.37%
-45.37%

More News

Read More
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
September 13, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know
December 19, 2023
Via Benzinga
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
September 09, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
August 14, 2024
Via Benzinga
PRLD Stock Earnings: Prelude Therapeutics Misses EPS for Q2 2024
August 12, 2024
Via InvestorPlace
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
July 09, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
June 22, 2024
Via Talk Markets
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
June 03, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
May 09, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024
May 07, 2024
Via InvestorPlace
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
April 09, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
March 05, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
February 29, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
February 16, 2024
Via Benzinga
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
February 15, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Prelude Therapeutics Announces $25 Million Private Placement
December 11, 2023
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
November 01, 2023
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday
October 19, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap